share_log

西南证券4月11日发布研报称，给予上海医药（601607.SH）买入评级。评级理由主要包括：1）事件：公司发布2023年年报；2）医药商业：加速布局商业网络覆盖，持续巩固领先地位；3）医药工业：围绕大品种战略，持续推进中药大品种培育战略；4）创新管线步入收获期，市场潜力巨大。（每日经济新闻）

Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical bu

Zhitong Finance ·  Apr 11 08:10
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical business: accelerating the layout of commercial network coverage and continuing to consolidate its leading position; 3) pharmaceutical industry: continuing to promote the cultivation strategy of large varieties of traditional Chinese medicine around the big variety strategy; 4) the innovation pipeline has entered the harvest period, and the market potential is huge. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment